Localization of promoter elements in the human mu-opioid receptor gene and regulation by DNA methylation

Molecular Brain Research

Volumn 70, Issue 1, 1999, Pages 54-65

  Andria, Matthew Louis ^a   Simon, Eric Jacob ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bisulfite; Polymerase chain reaction; Reporter gene; SH SY5Y; TATA box; Transfection

Indexed keywords

BISULFITE; COMPLEMENTARY DNA; DNA; MESSENGER RNA; MU OPIATE RECEPTOR;

ANIMAL CELL; ARTICLE; BRAIN; CELL STRAIN L 929; CONTROLLED STUDY; DNA METHYLATION; GENE CONTROL; GENE EXPRESSION; GENE LOCATION; GENE SEQUENCE; GENETIC TRANSFECTION; GENOME; HUMAN; HUMAN CELL; MOLECULAR CLONING; NEUROBLASTOMA CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SOUTHERN BLOTTING; START CODON; TATA BOX; TISSUE SPECIFICITY; TRANSCRIPTION INITIATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CPG ISLANDS; DNA METHYLATION; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; KIDNEY; L CELLS (CELL LINE); LUCIFERASES; MICE; NERVE TISSUE PROTEINS; NEUROBLASTOMA; ORGAN SPECIFICITY; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); RATS; RECEPTORS, OPIOID, MU; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033001995     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(99)00126-6     Document Type: Article

References (68)

1. Andria M.L., Ehrlich G.K., Simon E.J. Molecular characterization of a human mu-opioid receptor gene: demonstration of promoter activity. Regul. Pept. 54:1994;9-10.
2. Azaryan A.V., Coughlin L.J., Buzas B., Clock B.J., Cox B.M. Effect of chronic cocaine treatment on μ- and δ-opioid receptor mRNA levels in dopaminergically innervated brain regions. J. Neurochem. 66:1996;443-448.
3. Bird A. CpG-rich islands and the function of DNA methylation. Nature. 321:1986;209-213.
4. Brodsky M., Elliot K., Hynansky A., Inturrisi C.E. CNS levels of mu opioid receptor (MOR-1) mRNA during chronic treatment with morphine or naltrexone. Brain Res. Bull. 38:1995;135-141.
5. Burke T.W., Kadonaga J.T. Drosophila TFIID binds to a conserved downstream basal promoter element that is present in many TATA-bob-deficient promoters. Genes Dev. 10:1996;711-724.
6. Buzas B., Rosenberger J., Cox B.M. Mu and delta opioid receptor gene expression after chronic treatment with opioid agonist. NeuroReport. 7:1996;1505-1508.
7. Castelli M.P., Melis M., Mameli M., Fadda P., Diaz G., Gessa G.L. Chronic morphine and naltrexone fail to modify μ-opioid receptor mRNA levels in the rat brain. Mol. Brain Res. 45:1997;149-153.
8. Chan K., Brodsky M., Davis T., Franklin S., Inturrisi C.E., Yoburn B.C. The effect of irreversible μ-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA. Eur. J. Pharmacol. 44:1995;1119-1127.
9. Chen Y., Mestek A., Liu J., Hurley J.A., Yu L. Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol. Pharmacol. 44:1993;8-12.
10. Chuang T.K., Killiam K.F., Chuang L.F., Kung H.-F., Sheng W.S., Chao C.C., Yu L., Chuang R.Y. Mu opioid receptor gene expression in immune cells. Biochem. Biophys. Res. Commun. 216:1995;922-930.
11. Clark M.P., Chow C.-W., Rinaldo J.E., Chalkley R. Correct usage of multiple transcription initiation sites and C/EBP-dependent transcription activation of the rat XDH/XO TATA-less promoter requires downstream elements located in the coding region of the gene. Nucleic Acids Res. 26:1998;1801-1806.
12. Darlison M.G., Greten F.G., Harvey R.J., Kreienkamp H.-J., Stuhmer T., Zwiers H., Lederis K., Richter D. Opioid receptors from a lower vertebrate (Catostomus commersoni): sequence, pharmacology, coupling to a G-protein-gated inward-rectifying potassium channel (GIRK1), and evolution. Proc. Natl. Acad. Sci. U.S.A. 94:1997;8214-8219.
13. Delfs J.M., Yu L., Ellison G.D., Reisine T., Chesselet M.-F. Regulation of μ-opioid receptor mRNA in rat globus pallidus: effects of enkephalin increases induced by short- and long-term haloperidol administration. J. Neurochem. 63:1994;777-780.
14. Evans C.J., Keith D.E. Jr., Morrison H., Magendzo K., Edwards R.H. Cloning of a delta opioid receptor by functional expression. Science. 258:1992;1952-1955.
15. Franks R.R., Anderson R., Moore J.G., Hough-Evans B.R., Britten R.J., Davidson E.H. Competitive titration in living sea urchin embryos of regulatory factors required for expression of the CyIIIa actin gene. Development. 110:1990;31-40.
16. Gies E.K., Peters D.M., Gelb C.R., Knag K.M., Peterfreund R.A. Regulation of mu opioid receptor mRNA levels by activation of protein kinase C in human SH-SY5Y neuroblastoma cells. Anesthesiology. 87:1997;1127-1138.
17. Hsueh C.-T., Dolnick B.J. Regulation of folate-binding protein gene expression by DNA methylation in methotrexate-resistant KB cells. Biochem. Pharmacol. 47:1994;1019-1027.
18. Javahery R., Khachi A., Lo K., Zenzie-Gregory B., Smale S.T. DNA Sequence requirements for transcriptional initiator activity in mammalian cells. Mol. Cell. Biol. 14:1994;116-127.
19. Jhaveri M.S., Morrow C.S. Methylation-mediated regulation of the glutathione S-transferase P1 gene in human breast cancer cells. Gene. 210:1998;1-7.
20. Kass S.U., Pruss D., Wolffe A.P. How does DNA methylation repress transcription? Trends Genet. 13:1997;444-449.
21. Kaufmann J., Ahrens K., Koop R., Smale S.T., Muller R. CIF150, a human cofactor for transcription factor IID-dependent initiator function. Mol. Cell. Biol. 18:1998;233-239.
22. Kieffer B.L., Befort K., Gaveriaux-Ruff C., Hirth C.G. The δ-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. U.S.A. 89:1992;12048-12052.
23. Ko J.L., Minnerath S.R., Loh H.H. Dual promoters of mouse m-opioid receptor gene. Biochem. Biophys. Res. Commun. 234:1997;351-357.
24. Kraus J., Horn G., Zimprich A., Simon T., Mayer P., Hollt V. Molecular cloning and functional analysis of the rat m opioid receptor gene promoter. Biochem. Biophys. Res. Commun. 212:1995;591-597.
25. Kraus R.J., Murray E.E., Wiley S.R., Zink N.M., Loritz K., Gelembink G.W., Mertz J.E. Experimentally determined weight matrix definitions of the initiator and TBP binding site elements of promoters. Nucleic Acids Res. 24:1996;1531-1539.
26. Kurioka H., Kishi H., Isshiki H., Tagoh H., Mori K., Kitagawa T., Nagata T., Dohi K., Muraguchi A. Isolation and characterization of a TATA-less promoter for the human RAG-1 gene. Mol. Immunol. 33:1996;1059-1066.
27. Liang Y., Mestek A., Yu L., Carr L.G. Cloning and characterization of the promoter region of the mouse μ opioid receptor gene. Brain Res. 679:1995;82-88.
28. Liang Y., Carr L.G. Transcription of the mouse μ-opioid receptor gene is regulated by two promoters. Brain Res. 769:1997;372-374.
29. Lo K., Landau N.R., Smale S.T. LyF-1, a transcriptional regulator that interacts with a novel class of promoters for lymphocyte-specific genes. Mol. Cell. Biol. 13:1991;2982-2992.
30. Lo K., Smale S.T. Generality of a functional initiator consensus sequence. Gene. 182:1996;13-22.
31. Loh H.H., Liu H.-C., Cavalli A., Yang W., Chen Y.-F., Wei L.-N. μ Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Mol. Brain Res. 54:1998;321-326.
32. Lu S., Loh H.H., Wei L.-N. Studies of dual promoters of mouse κ-opioid receptor gene. Mol. Pharmacol. 52:1997;415-420.
33. A. Mansour, S.J. Watson, Anatomical distribution of opioid receptors in mammalians: an overview, in: A. Herz, (Ed.), Opioids, Vol. 1, Springer, Berlin, 1993, pp. 79-106.
34. Mansour A., Fox C.A., Thompson R.C., Akil H., Watson S.J. μ-Opioid receptor mRNA expression in the rat CNS: comparison to μ-receptor binding. Brain Res. 643:1994;245-265.
35. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., LeMear M., Dolle P., Tzavara E., Hanoune J., Rogne B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 383:1996;819-823.
36. Mayer P., Kraus J., Schulzeck S., Zimprich A., Koch T., Hollt V. Genomic organization of the rat μ opioid receptor. Analgesia. 1:1995;4-6.
37. Mayer P., Schulzeck S., Kraus J., Zimprich A., Hollt V. Promoter region and alternatively spliced exons of the rat μ-opioid receptor gene. J. Neurochem. 66:1996;2272-2278.
38. Min B.H., Augustin L.B., Felsheim R.F., Fuchs J.A., Loh H.H. Genomic structure and analysis of promoter sequence of a mouse μ opioid receptor gene. Proc. Natl. Acad. Sci. U.S.A. 91:1994;9081-9085.
39. Mummidi S., Ahuja S.S., McDaniel B.L., Ahuja S.K. The human CC chemokine receptor 5 (CCR5) gene. J. Biol. Chem. 272:1997;30662-30671.
40. Nan X., Campoy F.J., Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell. 88:1997;471-481.
41. Olek A., Oswald J., Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucl. Acids Res. 24:1996;5064-5066.
42. Parks C.L., Shenk T. The serotonin 1a receptor gene contains a TATA-less promoter that responds to MAZ and Sp1. J. Biol. Chem. 271:1996;4417-4430.
43. Pert C.B., Snyder S.H. Opiate receptor demonstration in nervous tissue. Science. 179:1973;1011-1014.
44. Petersen S.L., LaFlamme K.D. Progesterone increases levels of μ-opioid receptor mRNA in the preoptic area and arcuate nucleus of ovariectomized, estradiol-treated female rats. Mol. Brain Res. 52:1997;32-37.
45. Pscherer A., Dorflinger U., Kirfel J., Gawlas K., Ruschoff J., Buettner R., Schule R. The helix-loop-helix transcription factor SEF-2 regulates the activity of a novel initiator element in the promoter of the human somatostatin receptor II gene. EMBO J. 15:1996;6680-6690.
46. Ronnekleiv O.K., Bosch M.A., Cunnigham M.J., Wagner E.J., Grandy D.K., Kelly M.J. Downregulation of μ-opioid receptor mRNA in the mediobasal hypothalamus of the female guinea pig following morphine treatment. Neurosci. Lett. 216:1996;129-132.
47. Roy A.L., Du H., Gregor, Novina C.D., Martinez E., Roeder G. Cloning of an Inr- and E-box-binding protein, TFII-I, that interacts physically and functionally with USF1. EMBO J. 16:1997;7091-7104.
48. Ruzicka B.B., Thompson R.C., Watson S.J., Akil H. Interleukin-1β-mediated regulation of μ-opioid receptor mRNA in primary astrocyte-enriched cultures. J. Neurochem. 66:1996;425-428.
49. Schoenherr C.J., Anderson D.J. Silencing is golden: negative regulation in the control of neuronal gene transcription. Curr. Opin. Neurobiol. 5:1995;566-571.
50. Sedqi M., Roy S., Ramakrishnan S., Elde R., Loh H.H. Complementary DNA cloning of a μ-opioid receptor from rat peritoneal macrophages. Biochem. Biophys. Res. Commun. 209:1995;563-574.
51. Sehba F., Duttaroy A., Shah S., Chen B., Carroll J., Yoburn B.C. In vivo homologous regulation of μ-opioid receptor gene expression in the mouse. Eur. J. Pharacol. 339:1997;33-41.
52. Sibinga N.E.S., Goldstein A. Opioid peptides and opioid receptors in cells of the immune system. Annu. Rev. Immunol. 6:1988;219-250.
53. 3H -etorphine to rat brain homogenate Proc. Natl. Acad. Sci. U.S.A. 70:1973;1947-1949.
54. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., Miner L.L., Uhl G.R. Opiate receptor knockout mice define m receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. U.S.A. 94:1997;1544-1549.
55. W.M. Strauss, Preparation of genomic DNA from mammalian tissue, in: F.A. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, K. Struhl (Eds.), Current Protocols in Molecular Biology, Wiley, New York, 1997, pp. 2.2.1-2.2.5.
56. Tate P.H., Bird A.P. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev. 3:1993;226-231.
57. Terenius L. Characteristics of the 'receptor' for narcotic analgesics in synaptic plasma membrane fractions from rat brain. Acta Pharmacol. Toxicol. (Copenhagen). 33:1973;377-384.
58. Tian M., Broxmeyer H.E., Fan Y., Lai Z., Zhang S., Aronica S., Cooper S., Bigsby R.M., Steinmetz R., Engle S.J., Mestek A., Pollock J.D., Lehman M.N., Jansen H.T., Ying M., Stambrook P.J., Tischfield J.A., Yu L. Altered hematopoiesis, behavior, and sexual function in mu opioid receptor-deficient mice. J. Exp. Med. 185:1997;1517-1522.
59. Twyman R.M., Jones E.A. The regulation of neuron-specific gene expression in the mammalian nervous system. J. Neurogenet. 10:1995;67-101.
60. Unterwald E.M., Rubenfeld J.M., Spangler R., Imai Y., Wang J.B., Uhl G.R., Kreek M.J. Mu opioid receptor mRNA levels following chronic naltrexone administration. Regul. Pept. 52:1994;307-308.
61. Unterwald E.M., Rubenfeld J.M., Imai Y., Wang J.-B., Uhl G.R., Kreek M.J. Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Mol. Brain Res. 33:1995;351-355.
62. Usheva A., Shenk T. TATA-Binding protein-independent initiation: YY1, TFIIB, and RNA polymerase II direct basal transcription on supercoiled template DNA. Cell. 76:1994;1115-1121.
63. Vidal E.L., Patel N.A., Wu G.-d., Fiala M., Chang S.L. Interleukin-1 induces the expression of μ opioid receptors in endothelial cells. Immunopharmacology. 38:1998;261-266.
64. Virbasius C.A., Virbasius J.V., Scarpulla R.C. NRF-1, an activator involved in nuclear-mitochondrial interactions, utilizes a new DNA-binding domain conserved in a family of developmental regulators. Genes Dev. 7:1993;2431-2445.
65. Wang J.-B., Johnson P.S., Persico A.M., Hawkins A.L., Griffin C.A., Uhl G.R. Human μ opiate receptor: cDNA and genomic clones, pharmacological characterization and chromosomal assignment. FEBS Lett. 338:1994;217-222.
66. Xia L., Keith D.E. Jr., Evans C.E. Multiple opioid receptor-like genes are identified in diverse vertebrate phyla. FEBS Lett. 397:1996;25-29.
67. Zhou Q.-Y., Li C., Civelli O. Characterization of gene organization and promoter region of the rat dopamine D1 receptor gene. J. Neurochem. 59:1992;1875-1883.
68. Zhu Y., Hsu M.-S., Pintar J.E. Developmental expression of the μ, κ, and δ opioid receptor mRNAs in mouse. J. Neurosci. 18:1998;2538-2549.